Consider Myocarditis When Patients Treated with Immune Checkpoint Inhibitors Present with Ocular Symptoms. (28th March 2022)

• Record Type: Journal Article
• Authors: Rhee, John Y; Torun, Nurhan; Neilan, Tomas G; Guidon, Amanda C
• Is Part Of: Oncologist. Volume 27:Number 5(2022)
• Page Start: e402
• Page End: e405
• Publication Date: 2022-03-28
• Subjects: immune checkpoint inhibitor -- immune-related adverse events -- myocarditis -- diplopia -- myasthenia gravis; Oncology -- Periodicals; Tumors -- Periodicals; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Oncology; Tumors; Neoplasms; Electronic journals; Periodicals; Periodicals; 616.994
• DOI: 10.1093/oncolo/oyac033
• Languages: English
• ISSNs: 1083-7159

Abstract

Abstract : A potentially fatal non-neurologic immune-related adverse event is immune-related myocarditis. This article reports on three patients, presenting with symptoms of diplopia or ptosis, found to have concurrent myocarditis and immune-related myopathy or myasthenia gravis. Abstract: Immune checkpoint inhibitors (ICIs) have been associated with neurological immune related adverse events (irAE-N) and patients with ICI toxicity may present with neurological or ocular symptoms. Furthermore, patients on ICI may initially present to oncology or neurology. We report a case series of 3 patients treated with ICIs presenting with diplopia or ptosis, found to have concurrent myocarditis in addition to immune-related myopathy (irMyopathy) or myasthenia gravis (irMG). None of the patients described cardiac symptoms, underscoring the importance of screening for myocarditis in patients presenting with diplopia and/or other neuromuscular symptoms which may suggest either irMyopathy or irMG.